Gelteq Limited

Gelteq Limited

GELSPre-clinical

Gelteq Limited is a development-stage biotech company leveraging its proprietary gel technology platform to address significant unmet medical needs in drug delivery. The company is advancing a pipeline of reformulated and novel therapeutics, with a strategic focus on improving patient outcomes through enhanced bioavailability and controlled release. As a publicly listed entity on the Australian Securities Exchange, Gelteq is positioned to capitalize on partnerships and further development of its platform. Its core mission is to transform treatment paradigms in challenging therapeutic areas.

Market Cap
$8.1M
Employees
1-10
Focus
Biotech

GELS · Stock Price

USD 0.762.18 (-74.15%)

Historical price data

AI Company Overview

Gelteq Limited is a development-stage biotech company leveraging its proprietary gel technology platform to address significant unmet medical needs in drug delivery. The company is advancing a pipeline of reformulated and novel therapeutics, with a strategic focus on improving patient outcomes through enhanced bioavailability and controlled release. As a publicly listed entity on the Australian Securities Exchange, Gelteq is positioned to capitalize on partnerships and further development of its platform. Its core mission is to transform treatment paradigms in challenging therapeutic areas.

Technology Platform

Proprietary gel-based drug delivery platform designed to enhance solubility, stability, bioavailability, and controlled release of pharmaceutical compounds.

Funding History

3

Total raised: $27.5M

IPO$15MUndisclosedJun 15, 2021
Series A$10MUndisclosedMar 15, 2017
Seed$2.5MUndisclosedJun 15, 2015

Opportunities

Opportunities include securing licensing deals with pharma partners for its delivery platform, expanding its IP portfolio, and advancing its lead gel-formulated candidates into clinical trials for high-need neurological or ophthalmic indications.

Risk Factors

Key risks include technology failure, inability to secure necessary funding or partnerships, intense competition in drug delivery, and the inherent uncertainties of pharmaceutical R&D and regulatory pathways.

Competitive Landscape

Competes with numerous established drug delivery firms and small biotech innovators. Differentiation hinges on proving superior performance of its gel technology in enhancing drug profiles and creating strong, defensible intellectual property.

Company Info

TypePlatform
Employees1-10
LocationAustralia
StagePre-clinical
RevenuePre-revenue

Trading

TickerGELS
ExchangeASX

Contact

Therapeutic Areas

NeurologyOphthalmology
SIMILAR COMPANIES
Neuren Pharmaceuticals
Neuren Pharmaceuticals
Pre-clinical · Melbourne
Opthea
Opthea
Pre-clinical · Melbourne
PolyNovo
PolyNovo
Pre-clinical ·
Imugene
Imugene
Pre-clinical ·
Incannex Healthcare
Incannex Healthcare
Pre-clinical ·
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile